Nissay Asset Management Corp Japan ADV Sells 1,718 Shares of Stryker Co. (NYSE:SYK)

Nissay Asset Management Corp Japan ADV lessened its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 3.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 53,549 shares of the medical technology company's stock after selling 1,718 shares during the quarter. Nissay Asset Management Corp Japan ADV's holdings in Stryker were worth $19,658,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Brookstone Capital Management grew its position in shares of Stryker by 29.6% during the 4th quarter. Brookstone Capital Management now owns 3,094 shares of the medical technology company's stock worth $1,114,000 after buying an additional 706 shares during the period. Cooper Financial Group grew its position in shares of Stryker by 15.0% during the 4th quarter. Cooper Financial Group now owns 883 shares of the medical technology company's stock worth $318,000 after buying an additional 115 shares during the period. Signal Advisors Wealth LLC grew its position in shares of Stryker by 8.8% during the 4th quarter. Signal Advisors Wealth LLC now owns 2,105 shares of the medical technology company's stock worth $760,000 after buying an additional 170 shares during the period. SeaCrest Wealth Management LLC grew its position in shares of Stryker by 6.4% during the 4th quarter. SeaCrest Wealth Management LLC now owns 1,173 shares of the medical technology company's stock worth $422,000 after buying an additional 71 shares during the period. Finally, Oak Thistle LLC acquired a new stake in shares of Stryker during the 4th quarter worth approximately $271,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This trade represents a 14.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Stryker Stock Performance

Shares of NYSE SYK traded up $2.04 during mid-day trading on Friday, reaching $394.24. 1,113,972 shares of the company's stock were exchanged, compared to its average volume of 1,348,571. The firm has a market capitalization of $150.48 billion, a price-to-earnings ratio of 50.80, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a 50-day moving average price of $366.62 and a two-hundred day moving average price of $375.47.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.50 EPS. Analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date is Monday, June 30th. Stryker's payout ratio is 45.41%.

Analyst Ratings Changes

Several analysts recently issued reports on SYK shares. Evercore ISI reduced their price target on shares of Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. JPMorgan Chase & Co. lifted their price target on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Stifel Nicolaus lifted their price target on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Wells Fargo & Company lifted their price target on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Finally, Argus set a $450.00 price target on shares of Stryker in a research report on Monday, February 3rd. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Stryker presently has an average rating of "Moderate Buy" and an average target price of $427.05.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.